AstraZeneca (LSE:AZN) has entered an exclusive worldwide licensing agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), an oral EGFR inhibitor already approved in the US and China for a form of lung cancer.
The deal carries a $600m upfront payment to Dizal, plus up to $900m tied to development, regulatory and sales milestones, along with tiered royalties on global sales.
Zegfrovy treats adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations, a subset with treatment options after platinum-based chemotherapy fails.
Roughly one in four patients with EGFR-mutated NSCLC carries this or another atypical mutation, according to AstraZeneca, which already markets EGFR-targeted therapies including Tagrisso.
"AstraZeneca is a leader in treating EGFR-mutated lung cancer, and we are eager to add Zegfrovy to our world-class portfolio", said Dave Fredrickson, the company's Executive Vice President of Oncology Haematology.
Dizal recently reported positive Phase III results for Zegfrovy in first-line NSCLC treatment, presented at the American Society of Clinical Oncology's 2026 meeting and published in the New England Journal of Medicine.
A supplemental approval application covering that first-line use is now with the US Food and Drug Administration and China's drug regulator, both of which have granted the drug Breakthrough Therapy Designation for the expanded indication.
The transaction is expected to close in the second half of 2026, subject to customary closing conditions and regulatory clearances, and AstraZeneca said it does not affect its 2026 financial guidance.
